Immunex Enbrel Psoriatic Arthritis 12-Month Data To Follow sBLA Approval
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication
Immunex plans to submit 12-month, open-label Enbrel data in psoriatic arthritis patients following FDA's Jan. 16 approval of etanercept for the supplemental indication